Business Wire Feed
Henry Schein One Unveils the Next Era of Dentrix Ascend for DSOs and Growth-Focused Practices
New Packages Accelerate Revenue Through an Integrated, Agentic PlatformAMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the market leader in dental practice management systems, today unveiled the next era of Dentrix Ascend—introducing three new packages built on more...
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report
Report Highlights the Company’s Collaboration with GARDP to Develop NUZOLVENCE® (zoliflodacin) for Oral Suspension for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Pediatric PatientsWALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., more...
Centauri Therapeutics Granted FDA QIDP Status for CTX-187 Treatment of Gram-Negative Bacterial Infections
Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections Qualified Infectious Disease Product designation awarded for the development of antibacterials and antifungals intended to treat more...
Bausch + Lomb Launches R&D “Teach-in” Webinar Series
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D “Teach-in” webinar series that more...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
Based on DESTINY-Breast05 Phase III trial results which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1 If approved, AstraZeneca and Daiichi Sankyo’s ENHERTU has the potential to more...
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment.HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary more...
AN2 Therapeutics Announces $40 Million Private Placement Financing
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for more...
HeartBeam to Attend Investor and Industry Conferences in March, Focused on Providing Updates on Commercial Launch and Unveiling 12-Lead ECG Extended Wear Patch
SANTA CLARA--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that management will attend key investor and industry conferences in March 2026. HeartBeam more...
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD programPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #CELMoD--Bristol Myers Squibb (NYSE: BMY) today announced positive interim more...
Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis
Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo Tilrekimig (PF-07275315) was well-tolerated with a favorable safety profile Tilrekimig more...
Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions
Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit revenue and profit growth since 2021 Expected to be accretive to Agilent’s top-line growth rate, margin profile and more...
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to more...
Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin
Cetaphil’s new AM/PM Serums are powered by unique Gallic-AOX Power™ Technology, a patent-pending antioxidant complex clinically designed to sync to your skin’s circadian rhythm and support skin resilience Delivers advanced antioxidant protection by day1 and more...
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials Sotyktu is the first and more...
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe - The EC approval is based on results of the POD1UM-303 more...
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
-- Day 74 Letter Received from the U.S. Food and Drug Administration (FDA) Indicated the Agency Has No Plans to Convene an Advisory Committee -- -- Company has Submitted the Marketing Authorization Application (MAA) to more...
MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era
Peer-reviewed study in ACS Biomacromolecules demonstrates modular VHH potency, cross-variant therapeutic activity, and a newly described immune-priming mechanism; MindWalk holds first right to commercialize jointly developed intellectual propertyAUSTIN, Texas--(BUSINESS WIRE)--$HYFT #ai--MindWalk Holdings Corp. (NASDAQ: HYFT), more...
Alight to Participate in Upcoming Investor Conferences
CHICAGO--(BUSINESS WIRE)--Alight, Inc. (NYSE: ALIT), a leading provider of health, wealth, leave and point solutions, today announced that its Chief Executive Officer, Rohit Verma, will conduct one-on-one meetings and fireside chats at the upcoming investor more...
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG
DALLAS & NEW YORK & LONDON & TOKYO--(BUSINESS WIRE)--Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & more...
WELL Health to Report Fourth Quarter and Year End 2025 Financial Results on March 19, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)--WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (the “Company” or “WELL”), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients more...
VASA Fitness Opens 71st Club Nationwide with New Romeoville, IL Location
Brings high-value, full-service fitness experience to Will County communityROMEOVILLE, Ill.--(BUSINESS WIRE)--VASA Fitness, a leading high-value fitness brand redefining the gym experience, today announced the opening of its newest club in Romeoville, Illinois, with doors officially more...
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms Gazyva has the potential to become a new standard more...
Viper Partners Advises Vascular Specialists in Strategic Partnership with CUC America
PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--#ClinicalExcellence--Viper Partners, a healthcare-focused advisory firm, is pleased to announce that it served as the exclusive advisor to Vascular Specialists in its strategic partnership with CUC America, a leading healthcare services more...
AdvoCare® Introduces Rehydrate: Hydration + Energy
Performance Hydration and Steady Energy SolutionRICHARDSON, Texas--(BUSINESS WIRE)--#AdvoCareRehydrate--AdvoCare International, LLC, a leading health and wellness company, is pleased to introduce Rehydrate: Hydration + Energy. This new product delivers hydration and steady energy in one simple more...
GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®
GoodRx Employer Direct enables self-insured employers to subsidize the $449 Lilly Employer Connect medication price for Zepbound KwikPen to reduce employee out-of-pocket costs Brief Summary: GoodRx to collaborate with Eli Lilly to expand employer-sponsored access more...